Change 5-day change 1-year change 3-year change Capi.($)
+1.12%-1.04% - - 16.15M
+0.13%+1.50%+63.86%+123.95% 55.63B
+6.76%+22.83%+91.66%+101.42% 52.25B
+3.33%+3.71%-11.68%-11.82% 23.07B
+1.32%+9.33%+5.28%+419.80% 22.41B
+6.78%+14.47%+40.28%-6.67% 17.32B
+0.97%+5.01%+31.23%-32.10% 15.94B
-0.89%+4.57%+24.30%+185.83% 13.77B
+9.96%+19.81%+157.65%+320.70% 13.47B
+4.21%+4.76%+33.21% - 12.43B
Average +3.37%+6.84%+48.42%+137.64% 25.14B
Weighted average by Cap. +3.42%+7.62%+54.17%+128.96%
Logo Opexa Therapeutics Inc
Acer Therapeutics Inc. is a pharmaceutical company, which is focused on the acquisition, development and commercialization of therapies for serious rare and life-threatening diseases with significant unmet medical needs. The Company’s product pipeline includes OLPRUVA (sodium phenylbutyrate), ACER-801 (osanetant) and EDSIVO (celiprolol). OLPRUVA (sodium phenylbutyrate) for oral suspension is a formulation of sodium phenylbutyrate powder, for the treatment of various inborn errors of metabolism, including urea cycle disorders (UCDs) and Maple Syrup Urine Disease (MSUD). Its ACER-801 (osanetant) is an investigational non-hormonal, neurokinin 3 receptor (NK3R) antagonist for the treatment of asomotor symptoms (VMS), post-traumatic stress disorder (PTSD), and prostate cancer. Its EDSIVO (celiprolol) is a selective adrenergic modulator for the treatment of vascular Ehlers-Danlos syndrome (vEDS) in patients with a confirmed type III collagen (COL3A1) mutation.
Employees
-